GlassScriptPhysician profile
Kristen Rosser
NPI 1255138699
$3,014.98
in general payments reported to CMS, 2019-2025
26 companies · $3,015 in 2025
The $3,015 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $3,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,926 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,925.98 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $754.98 | 2025 | |
| Ucb, INC. | $311.60 | 2025 | Zilbrysq, Nayzilam, Fintepla |
| Janssen Biotech, INC. | $245.56 | 2025 | |
| Sk Life Science, INC. | $199.28 | 2025 | |
| Lundbeck LLC | $191.73 | 2025 | Vyepti |
| Eisai INC. | $186.16 | 2025 | |
| Lilly USA, LLC | $154.38 | 2025 | Kisunla, Amyvid |
| Pfizer INC. | $143.99 | 2025 | |
| Merz Pharmaceuticals, LLC | $100.79 | 2025 | Inbrija, Xeomin, Ampyra |
| Biogen, INC. | $93.78 | 2025 | Tysabri, Vumerity, Leqembi |
| Alexion Pharmaceuticals, INC. | $89.17 | 2025 | Ultomiris |
| Axsome Therapeutics, INC. | $66.95 | 2025 | Symbravo |
| Argenx US, INC. | $65.32 | 2025 | Vyvgart Hytrulo |
| Takeda Pharmaceuticals U.S.A., INC. | $50.85 | 2025 | Hyqvia |
| Acadia Pharmaceuticals INC | $44.60 | 2025 | Daybue |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $42.04 | 2025 | Qutenza |
| Teva Pharmaceuticals USA, INC. | $40.60 | 2025 | Austedo Xr, Ajovy |
| Tanabe Pharma America, INC. | $39.43 | 2025 | Radicava |
| Neurelis, INC. | $37.36 | 2025 | Valtoco |
| Csl Behring | $31.10 | 2025 | Hizentra |
| Otsuka America Pharmaceutical, INC. | $25.13 | 2025 | Rexulti |
| Genzyme Corporation | $23.08 | 2025 | |
| Amgen INC. | $20.85 | 2025 | Uplizna |
| Novartis Pharmaceuticals Corporation | $20.70 | 2025 | |
| Medtronic, INC. | $18.15 | 2025 | Percept PC Brainsense |
| Amneal Pharmaceuticals LLC | $17.40 | 2025 | Crexont |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Rosser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.